+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11358(SIPA1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P11358(SIPA1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The SIPA1 (Signal-Induced Proliferation-Associated 1) antibody targets a protein encoded by the *SIPA1* gene, which belongs to the GTPase-activating protein (GAP) family. SIPA1 regulates intracellular signaling by accelerating GTP hydrolysis in Rap GTPases, influencing cell proliferation, adhesion, and migration. Initially identified for its role in lymphocyte activation, SIPA1 is now studied extensively in cancer biology due to its association with tumor progression and metastasis. Overexpression of SIPA1 has been linked to aggressive phenotypes in breast, prostate, and colorectal cancers, where it promotes invasion and modulates extracellular matrix interactions.

SIPA1 antibodies are essential tools for detecting protein expression and localization in research. They are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess SIPA1 levels in cell lines or clinical samples. Available as monoclonal or polyclonal antibodies, they are typically raised in hosts like rabbits or mice, with specificity validated via knockout controls or siRNA silencing. Recent studies also explore SIPA1's role in tumor microenvironment regulation and therapeutic resistance, highlighting its potential as a prognostic biomarker or therapeutic target. These antibodies thus support both mechanistic insights and translational applications in oncology.